No press releases found.
VivoSim Labs Stockholders Approve Directors and Governance Matters
TipRanks (Thu, 18-Dec 4:37 PM ET)
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Vivosim Labs trades on the NASDAQ stock market under the symbol VIVS.
As of December 19, 2025, VIVS stock price climbed to $1.98 with 14,152 million shares trading.
VIVS has a beta of 2.66, meaning it tends to be more sensitive to market movements. VIVS has a correlation of 0.10 to the broad based SPY ETF.
VIVS has a market cap of $5.16 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that VIVS belongs to (by Net Assets): VXF.
VIVS support price is $1.81 and resistance is $2.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIVS shares will trade within this expected range on the day.
